These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39164549)

  • 1. Combining Killed Vaccine Candidate with Different Adjuvants to Determine Prophylactic Potential against Leishmaniasis.
    Kelleci K; Allahverdiyev A; Bağırova M; Ihlamur M; Abamor EŞ
    Acta Parasitol; 2024 Sep; 69(3):1613-1620. PubMed ID: 39164549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
    Thakur A; Kaur H; Kaur S
    Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
    Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
    Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
    Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
    Front Immunol; 2018; 9():465. PubMed ID: 29599776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine.
    Bhowmick S; Ravindran R; Ali N
    BMC Microbiol; 2014 Jan; 14():8. PubMed ID: 24428931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis.
    Bruhn KW; Birnbaum R; Haskell J; Vanchinathan V; Greger S; Narayan R; Chang PL; Tran TA; Hickerson SM; Beverley SM; Wilson ME; Craft N
    Clin Vaccine Immunol; 2012 Apr; 19(4):490-8. PubMed ID: 22323556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis.
    Oliveira-da-Silva JA; Lage DP; Ramos FF; Machado AS; Tavares GSV; Mendonça DVC; Pereira IAG; Martins VT; Carvalho LM; Ludolf F; Santos TTO; Reis TAR; Oliveira CS; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Menezes-Souza D; Roatt BM; Teixeira AL; Coelho EAF
    Mol Immunol; 2020 Aug; 124():161-171. PubMed ID: 32585510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis.
    de Oliveira Emerick S; Vieira de Carvalho T; Meirelles Miranda B; Carneiro da Silva A; Viana Fialho Martins T; Licursi de Oliveira L; de Almeida Marques-da-Silva E
    Vaccine; 2021 Jan; 39(2):282-291. PubMed ID: 33309484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice.
    Goyal DK; Keshav P; Kaur S
    Immunobiology; 2021 Mar; 226(2):152057. PubMed ID: 33545508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.
    Ostolin TLVDP; Gusmão MR; Mathias FAS; Cardoso JMO; Roatt BM; Aguiar-Soares RDO; Ruiz JC; Resende DM; de Brito RCF; Reis AB
    Vaccine; 2021 May; 39(20):2755-2763. PubMed ID: 33875268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.
    Costa LE; Goulart LR; Pereira NC; Lima MI; Duarte MC; Martins VT; Lage PS; Menezes-Souza D; Ribeiro TG; Melo MN; Fernandes AP; Soto M; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    PLoS One; 2014; 9(10):e110014. PubMed ID: 25333662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on cocktails of 31-kDa, 36-kDa and 51-kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis.
    Kaur H; Thakur A; Kaur S
    Parasite Immunol; 2015 Apr; 37(4):192-203. PubMed ID: 25615543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.